{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T20:15:42Z","timestamp":1791317742276,"version":"4.3.1"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001732","name":"Danmarks Grundforskningsfond","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001732","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.ejphar.2022.175397","type":"journal-article","created":{"date-parts":[[2022,11,19]],"date-time":"2022-11-19T10:53:09Z","timestamp":1668855189000},"page":"175397","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Improved metabolic efficacy of a dual amylin and calcitonin receptor agonist when combined with semaglutide or empagliflozin"],"prefix":"10.1016","volume":"938","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1844-3294","authenticated-orcid":false,"given":"Simone A.","family":"Melander","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Katri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten A.","family":"Karsdal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Henriksen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2022.175397_bib1","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1152\/ajpendo.00121.2014","article-title":"A novel oral dual amylin and calcitonin receptor agonist (KBP-042) exerts antiobesity and antidiabetic effects in rats","volume":"307","author":"Andreassen","year":"2014","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.ejphar.2022.175397_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2021.101282","article-title":"KBP-066A, a long-acting dual amylin and calcitonin receptor agonist, induces weight loss and improves glycemic control in obese and diabetic rats","volume":"53","author":"Andreassen","year":"2021","journal-title":"Mol. Metabol."},{"key":"10.1016\/j.ejphar.2022.175397_bib3","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/cld.650","article-title":"Glucagon-like peptide-1 analogues in nonalcoholic steatohepatitis: from bench to bedside","volume":"10","author":"Armstrong","year":"2017","journal-title":"Clin. Liver Dis."},{"key":"10.1016\/j.ejphar.2022.175397_bib4","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jhep.2015.08.038","article-title":"Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis","volume":"64","author":"Armstrong","year":"2016","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ejphar.2022.175397_bib5","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1210\/jc.2006-2003","article-title":"Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study","volume":"92","author":"Aronne","year":"2007","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejphar.2022.175397_bib6","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.jhep.2011.08.025","article-title":"The interaction of hepatic lipid and glucose metabolism in liver diseases","volume":"56","author":"Bechmann","year":"2012","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ejphar.2022.175397_bib7","doi-asserted-by":"crossref","first-page":"R945","DOI":"10.1152\/ajpregu.00275.2010","article-title":"Dose combinations of exendin-4 and salmon calcitonin produce additive and synergistic reductions in food intake in nonhuman primates","volume":"299","author":"Bello","year":"2010","journal-title":"Am. J. Physiol. Integr. Comp. Physiol."},{"key":"10.1016\/j.ejphar.2022.175397_bib8","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/s42255-020-0209-6","article-title":"Resolution of NASH and hepatic fibrosis by the GLP-1R and GCGR dual-agonist cotadutide via modulating mitochondrial function and lipogenesis","volume":"2","author":"Boland","year":"2020","journal-title":"Nat. Metab."},{"key":"10.1016\/j.ejphar.2022.175397_bib9","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.molmet.2017.11.009","article-title":"Amylin \u2013 its role in the homeostatic and hedonic control of eating and recent developments of amylin analogs to treat obesity","volume":"8","author":"Boyle","year":"2018","journal-title":"Mol. Metabol."},{"key":"10.1016\/j.ejphar.2022.175397_bib10","doi-asserted-by":"crossref","first-page":"633","DOI":"10.2337\/diab.45.5.633","article-title":"Abdominal fat and insulin resistance in normal and overweight women: direct measurements reveal a strong relationship in subjects at both low and high risk of NIDDM","volume":"45","author":"Carey","year":"1996","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2022.175397_bib11","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/s41574-018-0118-x","article-title":"Emerging hormonal-based combination pharmacotherapies for the treatment of metabolic diseases","volume":"15","author":"Clemmensen","year":"2019","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.ejphar.2022.175397_bib12","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.2337\/diabetes.51.4.1005","article-title":"The concurrent accumulation of intra-abdominal and subcutaneous fat explains the association between insulin resistance and plasma leptin concentrations : distinct metabolic effects of two fat compartments","volume":"51","author":"Cnop","year":"2002","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2022.175397_bib13","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.cld.2009.07.009","article-title":"Role of insulin resistance and lipotoxicity in non-alcoholic steatohepatitis","volume":"13","author":"Cusi","year":"2009","journal-title":"Clin. Liver Dis."},{"key":"10.1016\/j.ejphar.2022.175397_bib14","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1463-1326.2010.01330.x","article-title":"Liraglutide - overview of the preclinical and clinical data and its role in the treatment of type 2 diabetes","volume":"13","author":"Davies","year":"2011","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.ejphar.2022.175397_bib15","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1016\/S0140-6736(21)00845-X","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2\u00b74 mg for weight management: a randomised, controlled, phase 1b trial","volume":"397","author":"Enebo","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2022.175397_bib16","first-page":"92","article-title":"Jardiance (empagliflozin), an SGLT2 inhibitor, receives FDA approval for the treatment of patients with type 2 diabetes","volume":"8","author":"Fala","year":"2015","journal-title":"Am. Heal. drug benefits"},{"key":"10.1016\/j.ejphar.2022.175397_bib17","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/j.1476-5381.2012.01979.x","article-title":"Oral salmon calcitonin attenuates hyperglycaemia and preserves pancreatic beta-cell area and function in Zucker diabetic fatty rats","volume":"167","author":"Feigh","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2022.175397_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1172\/jci.insight.133429","article-title":"Semaglutide lowers body weight in rodents via distributed neural pathways","volume":"5","author":"Gabery","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.ejphar.2022.175397_bib19","doi-asserted-by":"crossref","first-page":"E598","DOI":"10.1152\/ajpendo.00419.2016","article-title":"Optimization of tolerability and efficacy of the novel dual amylin and calcitonin receptor agonist KBP-089 through dose escalation and combination with a GLP-1 analog","volume":"313","author":"Gydesen","year":"2017","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.ejphar.2022.175397_bib20","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/bph.13723","article-title":"A novel dual amylin and calcitonin receptor agonist, KBP-089, induces weight loss through a reduction in fat, but not lean mass, while improving food preference","volume":"174","author":"Gydesen","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2022.175397_bib21","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/bph.13723","article-title":"A novel dual amylin and calcitonin receptor agonist, KBP-089, induces weight loss through a reduction in fat, but not lean mass, while improving food preference","volume":"174","author":"Gydesen","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2022.175397_bib22","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.2337\/db07-1472","article-title":"Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats","volume":"57","author":"Han","year":"2008","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2022.175397_bib23","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ejphar.2015.05.051","article-title":"KBP-042 improves bodyweight and glucose homeostasis with indices of increased insulin sensitivity irrespective of route of administration","volume":"762","author":"Hjuler","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2022.175397_bib24","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1002\/oby.21563","article-title":"The dual amylin- and calcitonin-receptor agonist KBP-042 increases insulin sensitivity and induces weight loss in rats with obesity","volume":"24","author":"Hjuler","year":"2016","journal-title":"Obesity"},{"key":"10.1016\/j.ejphar.2022.175397_bib25","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1089\/dia.2013.0366","article-title":"Liraglutide's safety, tolerability, pharmacokinetics, and pharmacodynamics in pediatric type 2 diabetes: a randomized, double-blind, placebo-controlled trial","volume":"16","author":"Klein","year":"2014","journal-title":"Diabetes Technol. Therapeut."},{"key":"10.1016\/j.ejphar.2022.175397_bib26","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.2147\/DDDT.S58459","article-title":"Liraglutide and obesity: a review of the data so far","volume":"9","author":"Ladenheim","year":"2015","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.ejphar.2022.175397_bib27","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1080\/00325481.2019.1670017","article-title":"Combination therapy with SGLT-2 inhibitors and GLP-1 receptor agonists as complementary agents that address multi-organ defects in type 2 diabetes","volume":"131","author":"Lajara","year":"2019","journal-title":"Postgrad. Med."},{"key":"10.1016\/j.ejphar.2022.175397_bib28","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1124\/jpet.119.257576","article-title":"The dual amylin and calcitonin receptor agonist KBP-088 induces weight loss and improves insulin sensitivity superior to chronic amylin therapy","volume":"370","author":"Larsen","year":"2019","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejphar.2022.175397_bib29","doi-asserted-by":"crossref","DOI":"10.1186\/s12902-020-00678-2","article-title":"The dual amylin and calcitonin receptor agonist KBP-089 and the GLP-1 receptor agonist liraglutide act complimentarily on body weight reduction and metabolic profile","volume":"21","author":"Larsen","year":"2021","journal-title":"BMC Endocr. Disord."},{"key":"10.1016\/j.ejphar.2022.175397_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113842","article-title":"Does receptor balance matter? \u2013 comparing the efficacies of the dual amylin and calcitonin receptor agonists cagrilintide and KBP-336 on metabolic parameters in preclinical models","volume":"156","author":"Larsen","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejphar.2022.175397_bib31","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1016\/S0140-6736(21)01751-7","article-title":"Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial","volume":"398","author":"Lau","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2022.175397_bib32","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1111\/obr.12755","article-title":"Weight loss associated with sodium-glucose cotransporter-2 inhibition: a review of evidence and underlying mechanisms","volume":"19","author":"Lee","year":"2018","journal-title":"Obes. Rev."},{"key":"10.1016\/j.ejphar.2022.175397_bib33","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2020.617400","article-title":"Amylin and calcitonin: potential therapeutic strategies to reduce body weight and liver fat","volume":"11","author":"Mathiesen","year":"2021","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.ejphar.2022.175397_bib34","doi-asserted-by":"crossref","first-page":"9330","DOI":"10.3748\/wjg.v20.i28.9330","article-title":"Non-alcoholic fatty liver disease and obesity: biochemical, metabolic and clinical presentations","volume":"20","author":"Mili\u0107","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.ejphar.2022.175397_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes \u2013 state-of-the-art","volume":"46","author":"Nauck","year":"2021","journal-title":"Mol. Metabol."},{"key":"10.1016\/j.ejphar.2022.175397_bib36","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.pharmthera.2009.06.005","article-title":"Gut hormones: implications for the treatment of obesity","volume":"124","author":"Neary","year":"2009","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejphar.2022.175397_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2021.154925","article-title":"Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease","volume":"126","author":"Negi","year":"2022","journal-title":"Metabolism"},{"key":"10.1016\/j.ejphar.2022.175397_bib38","article-title":"Semaglutide subcutaneous once-weekly. Treatment to improve glycemic control in adults with type 2 diabetes mellitus","author":"Nordisk","year":"2017","journal-title":"Endocrinol. Metab. Drug Advis. Comm."},{"key":"10.1016\/j.ejphar.2022.175397_bib39","first-page":"227","article-title":"Liraglutide (Saxenda& lt;sup& gt;& #174;& lt;\/sup& gt;) as a Treatment for Obesity","volume":"7","author":"Onge","year":"2016","journal-title":"Food Nutr. Sci."},{"key":"10.1016\/j.ejphar.2022.175397_bib40","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(19)31271-1","article-title":"Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial","volume":"394","author":"Pratley","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2022.175397_bib41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7573\/dic.212585","article-title":"Clinical potential of treatment with semaglutide in type 2 diabetes patients","volume":"8","author":"R\u00f8der","year":"2019","journal-title":"Drugs Context"},{"key":"10.1016\/j.ejphar.2022.175397_bib42","article-title":"Review of pramlintide as adjunctive therapy in treatment of type 1 and type 2 diabetes","volume":"203","author":"Ryan","year":"2008","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.ejphar.2022.175397_bib43","series-title":"A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis","first-page":"1","author":"Sanyal","year":"2020"},{"key":"10.1016\/j.ejphar.2022.175397_bib44","first-page":"E620","article-title":"Pramlintide treatment reduces 24-h caloric intake and meal sizes and improves control of eating in obese subjects: a 6-wk translational research study","volume":"293","author":"Smith","year":"2007","journal-title":"Am. J. Physiol. Metab."},{"key":"10.1016\/j.ejphar.2022.175397_bib45","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.2337\/dc08-0029","article-title":"Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity","volume":"31","author":"Smith","year":"2008","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejphar.2022.175397_bib46","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1124\/jpet.119.263723","article-title":"The dual amylin and calcitonin receptor agonist, KBP-066, induces an equally potent weight loss across a broad dose range while higher doses may further improve insulin action","volume":"373","author":"Sonne","year":"2020","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejphar.2022.175397_bib47","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.3390\/biomedicines10102365","article-title":"The impact of exposure profile on the efficacy of dual amylin and calcitonin receptor agonist therapy","volume":"10","author":"Sonne","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.ejphar.2022.175397_bib48","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.redox.2017.06.009","article-title":"The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats","volume":"13","author":"Steven","year":"2017","journal-title":"Redox Biol."},{"key":"10.1016\/j.ejphar.2022.175397_bib49","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/sj.bjp.0705397","article-title":"GLP-1 derivative liraglutide in rats with \u03b2 -cell deficiencies: influence of metabolic state on \u03b2 -cell mass dynamics","volume":"140","author":"Sturis","year":"2003","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2022.175397_bib50","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/dom.12040","article-title":"No evidence of drug\u2010induced pancreatitis in rats treated with exenatide for 13 weeks","volume":"15","author":"Tatarkiewicz","year":"2013","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.ejphar.2022.175397_bib51","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1007\/s00125-018-4669-0","article-title":"The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure","volume":"61","author":"Thomas","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/j.ejphar.2022.175397_bib52","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1038\/ijo.2013.162","article-title":"Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults","volume":"38","author":"van Can","year":"2014","journal-title":"Int. J. Obes."},{"key":"10.1016\/j.ejphar.2022.175397_bib53","doi-asserted-by":"crossref","first-page":"265","DOI":"10.2147\/DMSO.S58786","article-title":"Combination of the sodium-glucose cotransporter-2 inhibitor empagliflozin with orlistat or sibutramine further improves the body-weight reduction and glucose homeostasis of obese rats fed a cafeteria diet","volume":"7","author":"Vickers","year":"2014","journal-title":"Diabetes, Metab. Syndrome Obes. Targets Ther."},{"key":"10.1016\/j.ejphar.2022.175397_bib54","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/j.1464-5491.2007.02333.x","article-title":"Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus","volume":"25","author":"Vilsb\u00f8ll","year":"2008","journal-title":"Diabet. Med."},{"key":"10.1016\/j.ejphar.2022.175397_bib55","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1177\/0269881117737401","article-title":"Combination therapy for obesity","volume":"31","author":"Wilding","year":"2017","journal-title":"J. Psychopharmacol."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299922006586?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299922006586?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T23:08:35Z","timestamp":1757977715000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299922006586"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":55,"alternative-id":["S0014299922006586"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2022.175397","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Improved metabolic efficacy of a dual amylin and calcitonin receptor agonist when combined with semaglutide or empagliflozin","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2022.175397","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"175397"}}